uniQure N.V.

QURE · NASDAQ

uniQure has a gene-therapy platform and clinical pipeline, but the latest filings show small revenue, large research spending, operating losses and a balance sheet that must fund trials through binary data and regulatory events.

Follow Add to Watchlist Ask Question

NASDAQ QURE Coverage Bootstrap uniQure N.V.

Latest ReportMay 20, 2026uniQure: the gene-therapy runway is still burning cashView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

Nasdaq

Clear tags

Latest Thesis

uniQure: the gene-therapy runway is still burning cash

May 20, 2026Research reportSlides available

Read report Open slides Discussion (0)

uniQure N.V.the gene-therapy runway is still burning cashMay 20, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

uniQure: the gene-therapy runway is still burning cashuniQure has a gene-therapy platform and clinical pipeline, but the latest filings show small revenue, large research spending, operating losses and a balance sheet that must fund trials through binary data and regulatory events.NASDAQMay 20, 2026Research reportRead Slides